ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy—phase II investigator-initiated trial (NCCH2412/MK015)

Background: Small bowel adenocarcinoma (SBA) is a rare cancer with limited treatment strategies beyond first-line platinum-based combination therapy and no established second-line standard. Our recent retrospective study showed that Nectin-4 is frequently highly expressed in SBA and is associated wi...

Полное описание

Библиографические подробности

Главные авторы:	H. Fujii, H. Hirano, T. Kudo, K. Tsuchihashi, H. Shoji, N. Okita, T. Hirose, A. Takashima, M. Yokoyama, M. Kawasaki, Y. Shuda, M. Naito, K. Ichikawa, K. Sekine, J. Sato, N. Yamamoto, K. Kato
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-06-01
Серии:	ESMO Gastrointestinal Oncology
Предметы:	small bowel adenocarcinoma enfortumab vedotin antibody–drug conjugate nectin-4 investigator-initiated trial
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2949819826000221
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!